Business Description
Pro Medicus Ltd
ISIN : AU000000PME8
Share Class Description:
ASX:PME: Ordinary SharesTotal Employee Number:
75Description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 87.82 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 136.56 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.6 | |||||
3-Year EBITDA Growth Rate | 33.2 | |||||
3-Year EPS without NRI Growth Rate | 37.3 | |||||
3-Year FCF Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | 36.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.17 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 23.79 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.82 | |||||
9-Day RSI | 81.96 | |||||
14-Day RSI | 78.81 | |||||
3-1 Month Momentum % | 7.04 | |||||
6-1 Month Momentum % | -43.3 | |||||
12-1 Month Momentum % | -54.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.22 | |||||
Quick Ratio | 6.22 | |||||
Cash Ratio | 4.55 | |||||
Days Inventory | 96.27 | |||||
Days Sales Outstanding | 97.72 | |||||
Days Payable | 11064.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.36 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | 37.7 | |||||
Forward Dividend Yield % | 0.37 | |||||
5-Year Yield-on-Cost % | 1.68 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.42 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.87 | |||||
Operating Margin % | 74.16 | |||||
Net Margin % | 97.59 | |||||
EBITDA Margin % | 77.38 | |||||
FCF Margin % | 50.08 | |||||
OCF Margin % | 53.16 | |||||
ROE % | 81.1 | |||||
ROA % | 60.34 | |||||
ROIC % | 73.76 | |||||
3-Year ROIIC % | 121.31 | |||||
ROC (Joel Greenblatt) % | 567.73 | |||||
ROCE % | 51.42 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 79.8 | |||||
Forward PE Ratio | 99.55 | |||||
PE Ratio without NRI | 79.8 | |||||
Shiller PE Ratio | 411.41 | |||||
Price-to-Owner-Earnings | 156.38 | |||||
PEG Ratio | 2.33 | |||||
PS Ratio | 77.9 | |||||
PB Ratio | 48.1 | |||||
Price-to-Tangible-Book | 50.99 | |||||
Price-to-Free-Cash-Flow | 155.5 | |||||
Price-to-Operating-Cash-Flow | 146.59 | |||||
EV-to-EBIT | 103.61 | |||||
EV-to-Forward-EBIT | 119.1 | |||||
EV-to-EBITDA | 99.29 | |||||
EV-to-Forward-EBITDA | 111.11 | |||||
EV-to-Revenue | 76.84 | |||||
EV-to-Forward-Revenue | 51.68 | |||||
EV-to-FCF | 148.07 | |||||
Price-to-GF-Value | 0.73 | |||||
Price-to-Projected-FCF | 19.33 | |||||
Price-to-DCF (Earnings Based) | 2.55 | |||||
Price-to-DCF (FCF Based) | 4.98 | |||||
Price-to-Median-PS-Value | 1.48 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.5 | |||||
Price-to-Graham-Number | 13.45 | |||||
| Price-to-Net-Current-Asset-Value | 116.23 | |||||
| Price-to-Net-Cash | 238.65 | |||||
Earnings Yield (Greenblatt) % | 0.97 | |||||
FCF Yield % | 0.65 | |||||
Forward Rate of Return (Yacktman) % | 20.32 |
Pro Medicus Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pro Medicus Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-24 10:00 | In 153 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-14 11:00 | In 51 days | ||
| Annual report for 2026 | 2026-08-14 | In 50 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-14 | In 50 days | ||
| AUD 0.320000 Cash Dividend | 2026-02-26 | 116.23 (+5.75%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 169.47 (+2.71%) | ||
| General meeting for 2025 | 2025-11-24 10:00 | 251.32 (+2.14%) | ||
| AUD 0.300000 Cash Dividend | 2025-09-03 | 294.67 (-1.74%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-14 11:00 | 297.15 (-2.37%) | ||
| Annual report for 2025 | 2025-08-14 | 297.15 (-2.37%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Visage Highlights One Platform AI-Optimized at SIIM26 | 2026-06-08 | ||
| Visage Elevates AI Optimized Enterprise Imaging at HIMSS26 | 2026-03-10 | ||
| Visage Propels AI Optimized Enterprise Imaging at RSNA 2025 | 2025-11-19 | ||
| Visage Achieves Authority to Operate (ATO) from the U.S. Department of Veterans Affairs | 2025-09-04 | ||
| Visage Transforms Imaging to the Cloud at RSNA 2024 | 2024-11-12 | ||
| Visage Leads with CloudPACS at SIIM 2024 | 2024-06-25 | ||
| Visage Soars with CloudPACS at RSNA 2023 | 2023-11-14 | ||
| Visage 7 Named Best in KLAS 2023 | 2023-02-08 | ||
| Visage Announces Support of Amazon HealthLake Imaging | 2022-11-27 | ||
| Visage Leads with CloudPACS at RSNA 2022 | 2022-11-14 |
Articles on Pro Medicus Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers